Opioid use disorder affects millions, and data shows access to addiction treatment options during pregnancy may depend on your race.
By Abby Engelhart
Millions of Americans are affected by opioid addiction, or opioid use disorder (OUD). There are three first-line treatments for the general public: methadone, naltrexone, and buprenorphine. Only methadone and buprenorphine are considered first-line treatments during pregnancy and are considered safe to begin while pregnant. However, new research suggests that access to these treatments while pregnant may depend on your race.
Don’t give up! Treatment retention is a long game
Having a supervised medication plan in place, in combination with therapy, is the preferred treatment for pregnant individuals with OUD, according to leading organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the Substance Abuse and Mental Health Services Administration (SAMHSA). OUD treatment retention (i.e., following the treatment plan long-term) is one of the biggest contributors to success in preventing overdose and mortality due to opioid use.
The use of a treatment medication as part of the treatment plan, rather than medically supervised withdrawal, is typically important for positive pregnancy outcomes. While previous studies have shown disparities in access to treatment and treatment retention in the general public, pregnancy-specific information has been limited thus far.
A team of researchers from Harvard Medical School, Harvard T.H. Chan School of Public Health, and Stanford University School of Medicine answered that question. They used public nationwide Medicaid data from 2010 to 2018, and evaluated data of pregnancies resulting in live births.
Treatment-based racial disparities in pregnancy
The study, like previous studies in non-pregnant populations, found that Black individuals are less likely to receive buprenorphine and are more likely to be referred to methadone clinics than White individuals. While buprenorphine and methadone are both considered effective treatments, they differ in practicality and how they impact life day-to-day. Buprenorphine treatment is typically far less complicated, as patients can be immediately prescribed medication to take at home, while, in the US, methadone treatment typically requires visits to a specific clinic location and patients may only be eligible for at-home treatment after prolonged visitations and meeting specific criteria.
The researchers also discovered that retention in buprenorphine treatment was lower for Black individuals than retention in methadone treatment, but not for White individuals. They noted, however, that the differences in medication administration between the two treatments may offer a plausible explanation for that finding. Further research is needed to determine that. Nevertheless, these variations provoke questions around potential healthcare disparities that could be contributing to a lack of retention and to the initial differences in treatment prescription.
RELATED: Can a Placebo Help Treat Opioid Use Disorder?
Future implications for healthcare during pregnancy
The research team noted that a key strength of their study was the use of a large, nationwide cohort. This sample allowed them to account for sociodemographic factors. The current research literature paints a picture of the gap between the potential health opportunities offered to White individuals compared to their Black counterparts. It shows significant differences in maternal mortality, gestational health outcomes, and adverse pregnancy outcomes based on racial and age discrepancies. These have real-life consequences, and future research can help shape policy and administrative decisions that promote equitable and better health outcomes.
This and prior studies show that opioid use disorder exacerbates the disparities and potential complications of pregnancy and maternal health care. Further understanding the contributing factors behind these disparities and adverse health outcomes can better inform policy decisions so we can shift toward fair, effective treatment plans.
This study was published in the peer-reviewed journal JAMA Psychiatry.
The information contained in this article is for informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.
Further resources
SAMHSA’s National Helpline, 1-800-662-HELP (4357), is a free, confidential, 24/7, 365-day-a-year treatment referral and information service (in English and Spanish) for individuals and families facing mental and/or substance use disorders. Visit SAMHSA (Substance Abuse and Mental Health Services Administration) online at https://www.samhsa.gov/find-help/helplines/national-helpline
For more news on women’s health, check out health topics through the World Health Organization. https://www.who.int/health-topics/women-s-health
References
American College of Obstetricians and Gynecologists. (2014). Health disparities in rural women (Committee Opinion No. 586). Obstetrics & Gynecology, 123, 384–388. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/02/health-disparities-in-rural-women
American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy (Committee Opinion No. 711). Obstetrics & Gynecology, 130, e81–e94. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy
Dydyk, A. M., Jain, N. K., & Gupta, M. (2024). Opioid use disorder: Evaluation and management. StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK553166/
Karakus, M., Welch, R., Tucker, M., et al. (2026). Associations between maternal opioid use disorder treatment and pregnancy outcomes. Journal of Perinatology, 46, 550–554. https://doi.org/10.1038/s41372-025-02480-1
Tran, P., Jreij, B., Sistani, F., & Shaya, F. T. (2023). Disparities in maternal mortality. Journal of Clinical and Translational Science, 7(1), e192. https://doi.org/10.1017/cts.2023.520
Zakoul, H., Lin, C. G., Straub, L., et al. (2026). Racial and ethnic disparities in treatment discontinuation in pregnant females with opioid use disorder. JAMA Psychiatry, 83(10), 1086–1089. https://doi.org/10.1001/jamapsychiatry.2026.2506
About the Author
Abby Engelhart is a mom, animal lover, and Appalachian native, fascinated with humans and human behavior. After earning a master’s degree in Experimental Psychology and working in research, her passion for accessible and digestible scientific information exploded. She now enjoys writing scientific articles to fuel this passion.
